Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing
Reexamination Certificate
2007-03-20
2007-03-20
Zara, Jane (Department: 1635)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
C514S008100, C514S023000, C514S049000, C514S053000, C514S054000, C514S789000
Reexamination Certificate
active
10089525
ABSTRACT:
This invention provides methods and compositions for treating and preventing atherosclerosis other undesired blood clotting. The methods for treating and preventing atherosclerosis and related conditions involve administering to a mammal an agent that reduces activity of an ST3Gal IV sialyltransferase, which results in enhanced clearance of von Willebrand Factor (vWF) from the mammal.
REFERENCES:
patent: 6280989 (2001-08-01), Kapitonov et al.
patent: 6376475 (2002-04-01), Marth et al.
patent: WO 98/54365 (1998-12-01), None
Tsuji, S. Molecular cloning and functional analysis of sialyltransferases. Jan. 1996 J. Biochem. vol. 120, pp. 1-13 (see entire document, especially p. 5, section 3).
Opalinska et al. 2002 Nucleic-acid therapeutics: Basic principles and recent applications. Nature Reviews-Drug Discovery vol. 1, pp. 503-514.
Branch 1998 A good antisense molecule is hard to find, TIBS, vol. 23, pp. 45-50.
Webster's II New Riverside University Dictionary 1994 The Riverside Publishing Company, pp. 933 and 944.
Carver-Moore, K. et al., “Low levels of erythroid and myeloid progenitors in thrombopoietin- andc-mpl-deficient mice,”Blood, 88(3):803-808 (Aug. 1, 1996).
Crocker, P. et al., “The potential role of sialoadhesin as a macrophage recognition molecule in health and disease,”Glycoconj. J., 14:601-609 (1997).
Gill, J. et al., “The effect of ABO blood group on the diagnosis of von Willebrand disease,”Blood, 69(6):1691-1695 (Jun. 1987).
Ginsburg, D. and Bowie, E.J., “Molecular genetics of von Willebrand disease,”Blood, 79(10):2507-2529 (May 15, 1992).
Gurney, A. et al., “Thrombocytopenia inc-mpl-deficient mice,”Science, 265:14451447 (Sep. 2, 1994).
Hall, R. et al., “The frequencies of ABO blood groups and of secretors of ABH group substances in peripheral arteriosclerosis,”Atherosclerosis, 14:241-246 (1971).
Kitagawa, H. and Paulson, J. et al., “Cloning of a novel α2,3-sialyltransferase that sialylates glycoprotein and glycolipid carbohydrate groups,”J. Biol. Chem., 269(2):1394-1401 (Jan. 14, 1994).
Lecine, P. et al., “Mice lacking transcription factor NF-E2 provide in vivo validation of the proplatelet model of thrombocytopiesis and show a platelet production defect that is intrinsic to megakaryocytes,”Blood, 92(5):1608-1616 (Sep. 1, 1998).
Meade, T.W. et al., “Haemostatic function and cardiovascular death: Early results of a prospective study,”The Lancet, 1:1050-1053 (May 17, 1980).
Mohlke, K. et al., “Mvwf, a dominant modifier of murine von Willebrand factor, results from altered lineage-specific expression of a glycosyltransferase,”Cell, 96:111-120 (Jan. 8, 1999).
Nichols, W. and Ginsburg, D., “von Willebrand Disease,”Medicine, 76(1):1-20 (1997).
Okajima, T. et al., “Molecular cloning of a novel α2,3-sialyltransferase (ST3Gal VI) that sialylates type II lactosamine structures on glycoproteins and glycolipids,”J. Biol. Chem., 274(17):11479-11486 (Apr. 23, 1999).
Orstavik, K. et al., “Possible effect of secretor locus on plasma concentration of factor VIII and von Willebrand factor,”Blood, 73(4):990-993 (Mar. 1989).
Ruggeri, Z. and Zimmerman, T., “Variant von Willebrand's disease: Characterization of two subtypes by analysis of multimetric composition of factor VIII/von Willebrand factor in plasma and platelets,”J. Clin. Invest., 65:1318-1325 (Jun. 1980).
Sasaki, K. et al., “Expression cloning of a novel Galβ(1-3/1-4)GlcNAc α2,3-sialyltransferase using lectin resistance selection,”J. Biol. Chem., 268(30):22782-22787 (Oct. 25, 1993).
Savage, B. et al., “Initiation of platelet adhesion by arrest onto fibrinogen or translocation on von Willebrand factor,”Cell, 84:289-297 (Jan. 26, 1996).
Sodetz, J. et al., “Carbohydrate on human factor VIII/von Willebrand factor,”J. Biol. Chem., 253(20):7202-7206 (Oct. 25, 1978).
Sodetz, J. et al., “Relationship of sialic acid to function andin vivosurvival of human factor VIII/von Willebrand factor protein,”J. Biol. Chem., 252(15):5538-5546 (Aug. 10, 1977).
Wagner, D. et al., “Initial glycosylation and acidic pH in the golgi apparatus are required for multimerization of von Willebrand factor,”J. Cell Biol., 102:1320-1324 (Apr. 1986).
Wilkie, A., “The molecular basis of genetic dominance,”J. Med. Genet., 31:89-98 (1994).
Ellies Lesley G.
Marth Jamey D.
The Regents of the University of California
Zara Jane
LandOfFree
Prevention of atherosclerosis and undesired blood clotting... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Prevention of atherosclerosis and undesired blood clotting..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Prevention of atherosclerosis and undesired blood clotting... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3732171